After Pfizer, Moderna Covid vaccine shows 94 percent efficacy

"We believe that our investments in mRNA delivery technology and manufacturing process development will allow us to store and ship our Covid-19 vaccine candidate at temperatures commonly found in readily available pharmaceutical freezers and refrigerators," Juan Andres, Chief Technical Operations and Quality Officer at Moderna told IANS.

Moderna's vaccine, created in collaboration with the National Institutes of Health, has 30,000 volunteers in its fold. The population received either the real vaccine or a dummy shot.

The independent monitoring board, which reports on safety data found that among 95 infections recorded, 90 came from the placebo group and only five from the vaccine group, "resulting in a point estimate of vaccine efficacy of 94.5 percent".

Another bright spot: All 11 "severe cases" occurred in the placebo group and none in the mRNA-1273 vaccinated group.

Pfizer and BioNTech had announced 90 percent efficacy of its vaccine candidate exactly a week ago. Taken together, these two vaccines are firmly on course to seek emergency use authorization from the US Food and Drug administration if results hold out in the final data crunch due soon.

Both Moderna and Pfizer-BioNTech use the 'mRNA' technology which means the vaccine is not embedded with the virus itself and therefore no risk of catching Covid-19 from the shot itself.

The vaccine is infused with a piece of genetic code that trains our immune system to recognize the spike protein on the surface of the virus - a lethal signature of the coronavirus.